Page 81 - An Evidence Review of Active Surveillance in Men With Localized Prostate Cancer

Table 5. Monitoring criteria in protocols with curative intent in chronological order of starting enrollment year

Center, Monitoring Gleason # biopsy cores /% PSA Imaging Behavioral Additional Triggers for
Country schedule score cores indication laboratory interventions
[Pubmed ID] tests
Enrollment
years
Baylor DRE and PSA any new Repeat TRUS PSA velocity – – – Definitive treatment
College of every 3 mo first yr Gleason guided sextant was calculated when objective
Medicine and and every 6 mo pattern 4 or biopsy was from 3 separate progression or
MSKCC, thereafter. 5 recommended at 6 recorded values patients’ requests.
US 106 mo: bilateral or in a 12-mo
[15017211] multifocal cancer, or period: > 0.75
> 4 cores with ng/ml/yr in 12
1984-2001 cancer mo, or 24 mo
McGill Univ., Every 3-6 mo PSA Gleason TRUS guided √ – √ – Clinical disease
Canada 26,107 and DRE pattern of 4 biopsy was done progression on DRE or
[18484590] annually or when repeated sextant
there was a change biopsy, patient
1987-2002 in DRE or PSA. preference, or rising
26
PSA level.
≥3 positive, or
>50% cancer in at
least 1 core
Univ. of Every 3-6 mo Progression Increase in tumor √ – Anxiety – Increase in tumor
Connecticut PSA, DRE every 6 in Gleason volume (increased related to volume, progression in
Health to 12 mo, score number or percent increasing Gleason score, onset
Center, US 108 rebiopsies of cores positive) PSA trend of urinary symptoms,
[18707696] recommended 2 yr change in DRE or
after initial biopsy patient request (due to
1990-2006 anxiety related to
increasing PSA trend).

41